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Abstract
Background: Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1
(CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in
postmenopausal women with early breast cancer. This analysis aimed to assess the association of selected germline
CYP19A1 and ESR1 SNPs with early-onset hot flashes, sweating and musculoskeletal symptoms in premenopausal
patients enrolled in the Tamoxifen and Exemestane Trial (TEXT).
Methods: Blood was collected from consenting premenopausal women with hormone-responsive early breast cancer,
randomly assigned to 5-years of tamoxifen plus ovarian suppression (OFS) or exemestane plus OFS. DNA was extracted
with QIAamp kits and genotyped for two CYP19A1 (rs4646 and rs10046) and three ESR1 (rs2077647, rs2234693 and
rs9340799) SNPs by a real-time pyrosequencing technique. Adverse events (AEs) were recorded at baseline and 3-
monthly during the first year. Associations of the genotype variants with grade ≥2 early-onset targeted AEs of hot
flashes/sweating or musculoskeletal events were assessed using logistic regression models.
Results: There were 2660 premenopausal patients with breast cancer in the intention-to-treat population of TEXT, and
1967 (74 %) are included in this translational study. The CYP19A1 rs10046 variant T/T, represented in 23 % of women, was
associated with a reduced incidence of grade ≥2 hot flashes/sweating (univariate odds ratio (OR) = 0.78; 95 % CI 0.63–0.
97; P = 0.03), more strongly in patients assigned exemestane + OFS (TT vs CT/CC: OR = 0.65, 95 % CI = 0.48–0.89) than
assigned tamoxifen + OFS (OR = 0.94, 95 % CI = 0.69–1.27, interaction P = 0.03). No association with any of the CYP19A1/
ESR1 genotypes and musculoskeletal AEs was found.
Conclusion: The CYP19A1 rs10046 variant T/T favors lower incidence of hot flashes/sweating under exemestane + OFS
treatment, suggesting endocrine-mediated effects. Based on findings from others, this SNP may potentially enhance
treatment adherence and treatment efficacy. We plan to evaluate the clinical impact of this polymorphism during time,
pending sufficient median follow up.
Trial registration: ClinicalTrials.gov NCT00066703, registered August 6, 2003.
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Background
Adjuvant endocrine therapy significantly prolongs disease-
free and overall survival in women with hormone-
receptor-positive early breast cancer, but it is associated
with several side effects, which may lead to early treat-
ment cessation [1–3]. In the combined analysis of the
Tamoxifen and Exemestane Trial (TEXT) and Suppression
of Ovarian Function Trial (SOFT) [4], comparing adjuvant
exemestane plus ovarian function suppression (OFS) with
tamoxifen plus OFS in premenopausal patients with breast
cancer, early cessation of OFS and the assigned oral endo-
crine treatment occurred in 16 % of patients receiving exe-
mestane +OFS and 11 % of those receiving tamoxifen +
OFS. Nonetheless, exemestane +OFS significantly im-
proved disease outcome compared to tamoxifen +OFS
after 5.7 years median follow up.
The acute onset of menopause induced by gonadotropin-
releasing-hormone analogues (GnRHa) is associated with
more frequent and severe side effects compared to natural
menopause, significantly impacting the quality of life of
young patients with breast cancer [5]. The most common
side effects associated with early menopause include vaso-
motor symptoms (hot flashes and sweating), decreased
libido, insomnia, and dyspareunia secondary to vaginal dry-
ness. The frequency and severity of hot flashes may depend
on the abrupt fall in circulating estrogen levels as observed
in several studies among women undergoing a natural
menopausal transition [6–8], although other factors also
play a role [9, 10]. While chemotherapy, OFS, and aroma-
tase inhibitors (AIs) directly lower circulating estrogen
levels, tamoxifen, a selective estrogen receptor modulator,
has both agonistic and antagonistic effects on estrogen sig-
naling [11]. In addition to menopausal symptoms, AIs are
frequently associated with joint and muscle pain [12], de-
creased bone density [13] and risk of fracture [3], which
appears to increase with better compliance with AIs [14].
Common genetic polymorphisms of the genes involved
in estrogen production and estrogen target genes have been
linked to breast cancer risk, prognosis, treatment response
and side effects. One of these genes, the CYP19A1, encodes
for the enzyme aromatase that promotes the bioconversion
of androgens to estrogens. Genetic variations at the
CYP19A1 locus may result in increased or decreased aro-
matase activity and influence concentrations of circulating
estrogens [15–17]. For example, the rs10046 and rs4646
variants, located in a 3’ untranslated region, were associated
with higher estradiol and estrone levels due to increased
aromatase activity. Alternatively, these variants could be
linked with other gene variants such as the rs749292, which
is associated with even higher estrogen levels [17]. A recent
review and meta-analysis analyzed the influence of com-
mon CYP19A1 polymorphisms on postmenopausal patients
with breast cancer treated with AIs [18], indicating a certain
heterogeneity between studies.
The estrogen receptor α (ESR1) gene was recently recog-
nized as a low-penetrance breast cancer susceptibility gene.
Numerous studies suggest an association between ESR1
gene polymorphisms and breast cancer risk [19]. However,
results have been controversial due to heterogeneous data
sources, differences in study designs, ethnic background,
disease status, and sample size. ESR1 is an important medi-
ator of endocrine pathways involved in breast cancer risk
and outcomes, including endocrine treatment response and
side effects. Genetic polymorphisms altering the expression
of ESR1 have been suggested to affect breast cancer suscep-
tibility [20]. In particular, the restriction enzymes XbaI
(rs9340799) and PvuII (rs2234693) have been extensively
evaluated. Both are located in the first intron of the ESR1
gene. The association between variant allele T of ESR1
PvuII (C > T) and breast cancer appears to be linked to a
higher transcriptional activity of the variant gene [21] and
correlated with circulating estrogen levels [22].
A recent meta-analysis [23] found that menopausal sta-
tus modifies breast cancer risk associated with ESR1 PvuII
(C > T), with premenopausal variant carriers being at
higher risk, possibly related to differences in circulating es-
trogen levels [22]. However, an updated meta-analysis re-
stricted the effect to the Asian population [24]. Another
meta-analysis of almost 19,000 individuals in eight Euro-
pean centers reported that ESR1 XbaI (A >G) protects
against overall fracture risk [25], suggesting an involvement
of these polymorphisms in bone metabolism. These ESR1
polymorphisms have also been described to be involved in
ovarian hyperstimulation response in assisted reproduction
studies [26], further highlighting their role in endocrine-
related mechanisms.
Within the phase III TEXT trial in which 2672 premeno-
pausal women were randomized to adjuvant therapy with
exemestane +OFS or tamoxifen +OFS, with or without ad-
juvant chemotherapy, we prospectively designed a transla-
tional research project for blood collection to investigate
the effect of selected single nucleotide polymorphisms
(SNPs) on treatment efficacy and toxicity. The purpose of
the current analysis was to investigate the association of
common genetic variants of CYP19A1 (rs10046, rs4646)
and ESR1 (rs2077647, rs2234693 and rs9340799) with
early-onset vasomotor and musculoskeletal symptoms.
Methods
Patients
TEXT is an International Breast Cancer Study Group
(IBCSG)-coordinated, randomized, phase III trial that
enrolled premenopausal women with histologically proven
estrogen receptor (ER) and/or progesterone receptor (PgR)-
positive early breast cancer. From November 2003 through
April 2011, patients were enrolled within 12 weeks from
surgery, prior to the initiation of any systemic adjuvant
therapy, and randomized to 5 years of exemestane +OFS
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or tamoxifen +OFS. OFS was achieved by monthly injec-
tion of the GnRHa triptorelin; bilateral oophorectomy or
ovarian irradiation was allowed after at least 6 months of
triptorelin. Chemotherapy was optional and, if adminis-
tered, triptorelin and chemotherapy were started concomi-
tantly; oral endocrine treatment was started after the
completion of chemotherapy, or if chemotherapy was not
administered, it was started 6 to 8 weeks after the initiation
of triptorelin, to allow for the suppression of ovarian
estrogen production.
Trial procedures
Targeted adverse events (AEs) were systematically
collected, using the Common Terminology Criteria for
Adverse Events (CTCAE) Version 3.0, at baseline and
every 3 months during the first year of treatment: hot
flashes was graded 1–3 (1, mild; 2, moderate; 3, interfer-
ing with activities of daily living (ADL)); sweating was
graded 1–2 (1, mild and occasional; 2, frequent or
drenching); and musculoskeletal symptoms, i.e., myalgia,
arthralgia (joint pain), stiffness, were graded 1–4 (1, mild
pain, not interfering with function; 2, moderate pain,
pain or analgesics interfering with function but not
interfering with ADL; 3, severe pain, pain or analgesics
severely interfering with ADL; 4, disabling). Depending
on institutional procedures, patients may have been sys-
tematically asked about targeted AEs during the clinical
visit, or targeted AEs may have been recorded in the
CRFs based on review of the medical reports.
Protocol amendment 2, dated July 2008, increased the
sample size and added the collection of a single whole
blood sample for DNA isolation for translational re-
search objectives, i.e., to investigate treatment tolerability
and disease outcome according to genetic polymor-
phisms. Samples and consent were prospectively col-
lected for approximately 600 patients enrolled after the
amendment, and approximately 2000 patients enrolled
prior to the amendment were asked to re-consent and
have samples collected at the next scheduled protocol
visit. The translational protocol targeted collection was
of 2000 total samples.
Blood collection, DNA extraction and genotyping assays
Venous blood was collected into EDTA-treated tubes pro-
vided by IBCSG and either processed and stored locally at
−80 °C or shipped immediately to the CALGB Pathology
Coordinating Office (USA and Canada), for DNA extrac-
tion and temporary storage, until shipping to the IBCSG
central biomarker laboratory at the European Institute of
Oncology for biobanking, DNA extraction (all countries
except USA and Canada) and genotyping. Genomic DNA
was extracted with QIAamp DNA Blood Kits (Qiagen,
Valencia, CA, USA), according to the manufacturer’s
instructions and extraction was performed by the auto-
mated platform “QIAcube” (Qiagen, Valencia, CA, USA).
The germline DNA samples were genotyped for SNPs
in CYP19A1 (rs4646 and rs10046) and ESR1 (rs207764,
rs2234693 and rs9340799). All samples were analyzed
using a real-time sequencing method called pyrosequenc-
ing (Diatech Pharmacogenetics S.r.l., Jesi, Italy). The DNA
was amplified by polymerase chain reaction (PCR) with
biotinylated primers on the Real-Time PCR Cycler “Rotor-
Gene TM 6000” (Corbett Research, Sydney, Australia),
whereas single-stranded DNA templates were prepared
using the PyroMark Vacuum Prep Workstation (Biotage,
Uppsala, Sweden). The pyrosequencing analysis was
performed on the PyroMarkTM Q96 ID instrument (Bio-
tage). Control samples, representing a complete set of ge-
notypes (wt/wt; wt/v; v/v) for all SNPs, were processed in
each run. No patient sample failed genotyping.
Statistical analysis
The analysis included 1967 patients from the TEXT
intention-to-treat population (ITT) who gave whole blood
for genetic profiling (Fig. 1). The endpoint of early-onset
hot flushes/sweating was defined as presence or absence of
grade 2 or grade 3 hot flashes or grade 2 sweating reported
at the 3 month or 6 month visits after randomization.
Early-onset musculoskeletal symptoms were defined as
presence or absence of grade 2–4 musculoskeletal symp-
toms reported at the visits at 3, 6, 9 or 12 months after
randomization.
Logistic regression modeling assessed the association of
the selected genotypes with presence of early-onset AEs.
The model also adjusted for patient characteristics at
randomization: age (<45 versus ≥45 years); menstruation
status (normal versus irregular versus persistent amenor-
rhea); body mass index (BMI) (normal (<25), overweight
(25–29.9) versus obese (≥30) kg/m2)); adjuvant chemo-
therapy use (yes versus no); treatment assignment (exe-
mestane +OFS versus tamoxifen +OFS); presence of hot
flashes/sweating of any grade at baseline; and presence of
musculoskeletal symptoms of any grade at baseline. Be-
cause concomitant medications may affect the reported
AE severity, the impact of relevant concomitant medica-
tion use (yes versus no) prior to or continuing at baseline,
or introduced during the relevant endpoint time period,
was investigated in a sensitivity analysis. Concomitant
medications, prescribed for any reason, that might affect
the severity of hot flashes/sweating included venlafaxine,
SSRIs, clonidine, gabapentin, pregabalin and herbals [27];
medications for musculoskeletal symptoms such as non-
steroidal anti-inflammatory drugs (NSAIDs), glucosamine,
corticosteroids, gabapentin, and pregabalin. The analyses
also assessed whether the association varied by treatment
assignment by including genotype variants-by-treatment
interaction in the logistic regression models.
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We first assessed SNP variant effects in an additive
genotype model that compared 0 versus 1 versus 2 minor
or variant alleles using a one-degree-of-freedom trend
test. The minor or variant homozygote effect was assessed
in a recessive model that compared the minor or variant
homozygote versus the combined heterozygote and wild-
type homozygote (reference group) using the chi-squared
test. Hardy-Weinberg equilibrium (HWE) for genotype
frequencies was tested using the Monte Carlo simulation
method [28] to calculate the P value in order to avoid the
reliance on the underlying chi-square approximation.
The study is presented in accordance with the Reporting
Recommendations for Tumor Marker Prognostic Studies
(REMARK) criteria [29]. All statistical tests were two-sided,
without adjustment for multiple comparisons, and a P
value <0.05 in the overall cohort or interaction P value
≤0.10 was considered as statistically significant. For a given
sample size, assuming 10 % or 20 % homozygous variant
and 43 % and 26 % AE rates, the detectable differences in
AE rates for homozygous versus combined heterozygous
and wild-type would be in the range of 11 % to 7.2 % (Fish-
er’s exact test, two-sided α = 0.05, power ≥80 %).
Results
Study population
Blood for germline DNA extraction from 1967 consenting
women was collected and assessed, representing 74 % of
the entire TEXT ITT population of 2660 (Fig. 1). Patients
in the analytical cohort were representative of the TEXT
trial (Table 1), with the exceptions of race (one country did
not participate and some centers with a majority of hispanic
ethnicity had low participation rates) and early discontinu-
ation of protocol treatment (retrospective nature of sample
collection). Most patients were Caucasian (92 %), median
age was 44 years and median body mass index was 24 kg/
m2. Adjuvant chemotherapy was given to 58 % of patients.
At baseline, any grade (≥1) of hot flashes and sweating
were reported in 8 % and 7 % of patients, respectively,
while any grade (≥1) of musculoskeletal symptoms were
reported in 15 % of patients (Table 1).
The reference SNP numbers, minor allele frequencies
and genotype frequencies for each analyzed SNP are
listed in Table 2. No deviations from Hardy-Weinberg
equilibrium were observed. Occurrence and grade of hot
flashes, sweating and musculoskeletal side effects during
the first year of protocol therapy, overall and by treat-
ment assignment, are depicted in Table 3.
Association of CYP19A1 and ESR1 with early-onset hot
flashes/sweating
A total of 43 % of patients reported early-onset grade 2–3
hot flashes/sweating during the first 6 months of protocol
treatment (42 % of women receiving exemestane +OFS
(411/987) and 45 % of women allocated to tamoxifen +
OFS (437/980)). Most side effects were reported by the
month-3 visit (Table 3). Overall, patients with CYP19A1
rs10046 (C > T) minor variant (T/T) had a 22 % reduced
odds of reporting early-onset grade 2–3 hot flashes/sweat-
ing (odds ratio (OR) = 0.78, 95 % CI 0.63–0.97; P = 0.03)
when compared to patients with the C/T or C/C variants.
Excluded from translational cohort (N=345)
• Patient declined (N=93)
• Physician decision not to ask patient (N=3)
• Died prior to initiation of collect (N=19)
TEXT
ITT population
(N=2660)
T+OFS (N=1328)E+OFS (N=1332)
T+OFS (N=980)E+OFS (N=987)
TEXT
Translational Cohort
(N=1967)
• Withdrew consent or LFU prior to collection (N=67)
• Difficulties with patient contact/scheduling (N=2)
• Collected but not received at central lab (N=7)
• Site error/reason not reported (N=12)
• Site decision not to collect blood (34 centers) (N=82)
• No CRF/no sample, reason unknown (N=60)
Excluded from translational cohort (N=348)
• Patient declined (N=83)
• Physician decision not to ask patient (N=7)
• Died prior to initiation of collect (N=12)
• Withdrew consent or LFU prior to collection (N=55)
• Difficulties with patient contact/scheduling (N=6)
• Collected but not received at central lab (N=17)
• Site error/reason not reported (N=8)
• Site decision not to collect blood (34 centers) (N=82)
• No CRF/no sample, reason unknown (N=78)
Fig. 1 Derivation of the Tamoxifen and Exemestane Trial (TEXT) translational cohort from the intention-to-treat (ITT) population. The translational
cohort includes patients whose blood was available for DNA analysis. GNRHa triptorelin was required for the first 6 months, any time after which
the patient could choose to undergo bilateral oophorectomy or bilateral ovarian radiotherapy. E exemestane, T tamoxifen, OFS ovarian function
suppression, LFU lost to follow up, CRF case report form
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The effect was consistent, showing a multivariable OR of
0.83 (95 % CI 0.66–1.04; P = 0.10) after adjusting for
patient and treatment characteristics and concomitant
medications (Table 4). A differential effect according to
treatment assignment (treatment-by-genotype interaction,
P = 0.03) was observed for the association between
CYP19A1 rs10046 (C > T) genotype variants and early-
onset hot flashes/sweating. Patients treated with exemes-
tane +OFS and having the T/T variant had a 35 % reduced
odds of early-onset hot flashes/sweating (Table 5; univari-
ate OR = 0.65, 95 % CI 0.48–0.89; multivariable OR = 0.67,
95 % CI 0.49–0.93), which was not apparent for patients
treated with tamoxifen +OFS (univariable OR = 0.94, 95 %
CI 0.69–1.27; multivariable OR = 1.04, 95 % CI 0.75–1.43).
There was no statistically significant association between
the other four SNPs of CYP19A1 or ESR1 and early-onset
hot flashes/sweating side effects.
Association of CYP19A1 and ESR1 with early-onset muscu-
loskeletal symptoms
Within the first year of treatment, 26 % of patients reported
early-onset grade 2–4 musculoskeletal symptoms (34 % of
patients (331/987) assigned to exemestane +OFS and 19 %
of patients (185/980) assigned to tamoxifen +OFS. There
Table 1 Characteristics of TEXT intention-to-treat population, overall and according to availability of blood for DNA analysis
Blood for DNA analysis TEXT population
(n = 2660)
No (n = 693) Yes (n = 1967)
Characteristics at randomization
White/Caucasian,% 73 92 87
Age (years), median (IQR) 43 (39, 46) 44 (40, 47) 43 (40, 46)
Normal menstruation, % 87 88 87
BMI (kg/m2), median (IQR) 24 (22, 29) 24 (21, 28) 24 (21, 28)
Presence of any grade (1–3) hot flashes, % 5 8 7
Presence of any grade (1–2) sweating, % 4 7 6
Presence of any grade (1–4) musculoskeletal symptoms, % 13 15 15
Concomitant adjuvant therapy
Adjuvant chemotherapy, % 64 58 59
HER2-directed therapy, % 3 7 6
Protocol adjuvant therapy
Treatment assignment
Exemestane + OFS, % 50 50 50
Tamoxifen + OFS, % 50 50 50
Oral endocrine therapy (exemestane or tamoxifen) treatment <12 months, % 19 6 10
OFS <12 months, % 16 4 7
Analysis endpointsa
Early-onset grade ≥2 hot flashes/sweating, % 41 43 43
Early-onset grade ≥2 musculoskeletal symptoms, % 28 26 27
aAdverse events according to common terminology criteria for adverse events (CTCAE) v3.0 of hot flashes and/or sweating reported at 3 or 6 months after
randomization; musculoskeletal symptoms, i.e., myalgia, arthralgia (joint pain), or stiffness, reported at 3, 6, 9 or 12 months after randomization. TEXT Tamoxifen
and Exemestane Trial, BMI body mass index, IQR interquartile range, HER2 human epidermal growth factor receptor 2, OFS ovarian function suppression
Table 2 Minor allele frequency and genotype of the five genotyped SNPs in CYP19A1 and ESR1
Genotype, n (%)
Gene SNP Number assessed Minor allele frequency Wild-type Heterozygous Homozygous HWE P value
CYP19A1 rs4646 (G > T) 1967 0.29 989 (50) 822 (42) 156 (8) 0.44
CYP19A1 rs10046 (C > T) 1967 0.48 532 (27) 989 (50) 446 (23) 0.75
ESR1 rs2077647 (A > G) 1967 0.47 550 (28) 999 (51) 418 (21) 0.39
ESR1 rs2234693 (Pvull) (T > C) 1967 0.45 594 (30) 993 (50) 380 (19) 0.36
ESR1 rs9340799 (Xbal) (A > G) 1967 0.36 806 (41) 923 (47) 238 (12) 0.30
CYP19A1 Cytochrome P450 19A1, ESR1 Estrogen receptor 1, HWE Hardy-Weinberg equilibrium, SNP single nucleotide polymorphism
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Table 3 Analysis endpoints and side effects during first year of protocol therapy according to treatment assignment
Treatment
Overall Exemestane + OFS Tamoxifen + OFS
(n = 1967a) (n = 987) (n = 980)
Analysis endpoint
Early-onset hot flashes/sweating, grade ≥2 848 (43) 411 (42) 437 (45)
Early-onset musculoskeletal symptoms, grade ≥2 516 (26) 331 (34) 185 (19)
Side effect and time point Grade
Hot flashes
Baseline Unk 2 (0) 2 (0) 0 (0)
Gr0 1812 (92) 924 (94) 888 (91)
Gr1 134 (7) 51 (5) 83 (8)
Gr2 19 (1) 10 (1) 9 (1)
3 months Unk 8 (0) 3 (0) 5 (1)
Gr0 637 (32) 325 (33) 312 (32)
Gr1 766 (39) 386 (39) 380 (39)
Gr2 500 (25) 248 (25) 252 (26)
Gr3 56 (3) 25 (3) 31 (3)
6 months Unk 20 (1) 9 (1) 11 (1)
Gr0 525 (27) 294 (30) 231 (24)
Gr1 797 (41) 401 (41) 396 (40)
Gr2 573 (29) 260 (26) 313 (32)
Gr3 52 (3) 23 (2) 29 (3)
Sweating
Baseline Unk 3 (0) 3 (0) 0 (0)
Gr0 1832 (93) 920 (93) 912 (93)
Gr1 119 (6) 56 (6) 63 (6)
Gr2 13 (1) 8 (1) 5 (1)
3 months Unk 9 (0) 4 (0) 5 (1)
Gr0 1332 (68) 675 (68) 657 (67)
Gr1 444 (23) 219 (22) 225 (23)
Gr2 182 (9) 89 (9) 93 (9)
6 months Unk 22 (1) 9 (1) 13 (1)
Gr0 1285 (65) 688 (70) 597 (61)
Gr1 447 (23) 206 (21) 241 (25)
Gr2 213 (11) 84 (9) 129 (13)
Musculoskeletal symptoms
Baseline Unk 3 (0) 3 (0) 0 (0)
Gr0 1669 (85) 837 (85) 832 (85)
Gr1 248 (13) 125 (13) 123 (13)
Gr2 47 (2) 22 (2) 25 (3)
Gr3 0 (0) 0 (0) 0 (0)
3 months Unk 9 (0) 5 (1) 4 (0)
Gr0 1360 (69) 670 (68) 690 (70)
Gr1 467 (24) 231 (23) 236 (24)
Gr2 118 (6) 74 (7) 44 (4)
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was no statistically significant association between any of
the five SNPs of CYP19A1 and ESR1 and early-onset mus-
culoskeletal side effects (Table 4), nor of treatment-by-
genotype interaction. The presence of CYP19A1 rs10046
(C >T) minor variant (T/T) was not associated with early-
onset grade 2–4 musculoskeletal symptoms (univariate OR
= 0.90, 95 % CI 0.70–1.15; P = 0.39; OR = 0.84, 95 % CI
0.65–1.09; P = 0.18 after adjusting for patient and treatment
characteristics and concomitant medications (Table 4).
There was no evidence of a differential effect according to
treatment assignment (exemestane +OFS, OR = 0.97, 95 %
CI 0.71–1.33 versus tamoxifen +OFS, OR = 0.77, 95 % CI
Table 3 Analysis endpoints and side effects during first year of protocol therapy according to treatment assignment (Continued)
Gr3 13 (1) 7 (1) 6 (1)
6 months Unk 21 (1) 9 (1) 12 (1)
Gr0 1070 (54) 463 (47) 607 (62)
Gr1 648 (33) 366 (37) 282 (29)
Gr2 198 (10) 128 (13) 70 (7)
Gr3 30 (2) 21 (2) 9 (1)
9 months Unk 41 (2) 24 (2) 17 (2)
Gr0 995 (51) 386 (39) 609 (62)
Gr1 670 (34) 392 (40) 278 (28)
Gr2 228 (12) 159 (16) 69 (7)
Gr3 33 (2) 26 (3) 7 (1)
12 months Unk 37 (2) 23 (2) 14 (1)
Gr0 965 (49) 388 (39) 577 (59)
Gr1 708 (36) 400 (41) 308 (31)
Gr2 235 (12) 158 (16) 77 (8)
Gr3 22 (1) 18 (2) 4 (0)
Reports of hot flashes and sweating side effects and of musculoskeletal symptoms according to common terminology criteria for adverse events (CTCAE) v3.0 at time
points during the first year of protocol therapy. All data are summarized as number (%) of patients. aPatients without any adverse event data (two patients without hot
flashes/sweating and one without musculoskeletal symptoms) were excluded from summary. Unk unknown, Gr grade OFS ovarian function suppression
Table 4 Associations of CYP19A1 and ESR1 genotypes with analysis endpoints
Univariate model Multivariableb model Multivariablec model
Gene: SNP Comparisons Numbera (events) Odds ratio
(95 % CI)
P value Odds ratio
(95 % CI)
P value Odds ratio
(95 % CI)
P value
Hot flashes/sweating
CYP19A1: rs4646 Dose effectd 1965 (848) 1.05 (0.91,1.21) 0.50 1.04 (0.90,1.20) 0.63 1.08 (0.93,1.25) 0.30
CYP19A1: rs10046 T/T vs. C/T,C/C (ref) 446 (172) vs. 1519 (676) 0.78 (0.63,0.97) 0.03 0.82 (0.66,1.02) 0.08 0.83 (0.66,1.04) 0.10
ESR1:rs2077647 Dose effect 1965 (848) 0.95 (0.84,1.08) 0.47 0.96 (0.84,1.09) 0.51 0.97 (0.85,1.11) 0.69
ESR1:rs2234693 (PvuII) Dose effect 1965 (848) 0.92 (0.80,1.04) 0.18 0.92 (0.80,1.04) 0.19 0.94 (0.82,1.07) 0.36
ESR1:rs9340799 (XbaI) Dose effect 1965 (848) 0.94 (0.82,1.08) 0.38 0.94 (0.82,1.07) 0.34 0.98 (0.85,1.12) 0.73
Musculoskeletal symptoms
CYP19A1: rs4646 Dose effectd 1966 (516) 1.01 (0.86,1.18) 0.90 1.05 (0.89,1.24) 0.55 1.11 (0.93,1.31) 0.25
CYP19A1: rs10046 T/T vs. C/T,C/C (ref) 446 (110) vs. 1520 (406) 0.90 (0.70,1.15) 0.39 0.86 (0.66,1.10) 0.23 0.84 (0.65,1.09) 0.18
ESR1:rs2077647 Dose effect 1966 (516) 1.08 (0.94,1.25) 0.28 1.12 (0.96,1.30) 0.15 1.11 (0.95,1.29) 0.20
ESR1:rs2234693 (PvuII) Dose effect 1966 (516) 1.03 (0.90,1.19) 0.65 1.07 (0.92,1.25) 0.37 1.06 (0.91,1.24) 0.47
ESR1:rs9340799 (XbaI) Dose effect 1966 (516) 1.06 (0.91,1.23) 0.44 1.10 (0.94,1.29) 0.22 1.11 (0.94,1.30) 0.22
Analysis endpoints were early-onset (within 6 months) grade ≥2 hot flashes/sweating or (within 12 months) grade ≥2 musculoskeletal symptoms. aPatients without
any adverse event data, excluded from analyses (2 without hot flashes/sweating and one without musculoskeletal symptoms). bMultivariable logistic regression
model adjusted for characteristics: age, menstruation status, BMI, adjuvant chemotherapy use, treatment assignment, and presence of hot flashes/sweating at
baseline or of musculoskeletal symptoms at baseline (according to endpoint). cMultivariable model also adjusted for relevant concomitant medications prior to or
continuing at baseline, and use during relevant time period for the endpoint. dDose effect: comparisons of variant (Var) allele groups: 0 (Var) vs. 1 (Var) vs. 2 (Var).
SNP single nucleotide polymorphism
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0.52–1.16, treatment-by-genotype interaction; P = 0.39 from
the univariate model). The results were consistent after
adjusting for patient and treatment characteristics and con-
comitant medications (exemestane +OFS, OR = 0.96, 95 %
CI 0.69–1.32 versus tamoxifen +OFS, OR = 0.77, 95 % CI
0.51 − 1.17) (Table 5).
Discussion
This study provides evidence that CYP19A1 rs10046
variant carriers may face milder vasomotor symptoms
under combined endocrine treatment. Notably, the effect
was restricted to patients under OFS combined with
exemestane (treatment-by-genotype interaction, P =
0.03) and not tamoxifen, after adjusting for patient char-
acteristics and concomitant medications, including the
selective serotonin-reuptake inhibitors known to reduce
hot flashes/sweating.
This finding is in line with evidence from others, link-
ing this SNP to enhanced aromatase activity and higher
circulating estrogens [15, 17] and underscores a possible
relationship between the effect of this variant poly-
morphism (T/T), hot flashes/sweating and exemestane
activity. This result may in fact be related to less effect-
ive estrogen suppression by exemestane + OFS in these
women as a consequence of higher circulating estrogens
compared to patients with wild-type SNPs, although the
exact mechanism by which this SNP may affect exemes-
tane efficacy in suppressing the aromatase activity is not
known. One study recently reported similar associations
in postmenopausal patients with breast cancer [30]
enrolled in the TEAM trial: CYP19A1 variants linked
with lower estrogen levels were associated with in-
creased risk of early vasomotor and musculoskeletal
symptoms under exemestane. The TEAM substudy,
however, only included 27 % of the patients enrolled, less
than two-thirds of patients, which represents a smaller
proportion than is recommended by Simon et al. for
evaluating predictive biomarkers [31].
The ELPh trial was designed to address genetic associ-
ations with toxicity-related discontinuation of AI therapy
for breast cancer [32], including the SNP rs10046. The
authors did not specifically report on vasomotor symp-
toms, but did not find any relationship between rs10046
and toxicity-related treatment discontinuation. In an-
other study, in which the impact of CYP19A1 SNPs with
estrogen suppression during letrozole treatment was
assessed, the degree of suppression was independent of
the SNPs [33].
To our knowledge this is the first study to evaluate the
associations between common germline polymorphisms
of the CYP19A1 and ESR1 genes and early-onset side ef-
fects under combined endocrine treatment in premeno-
pausal patients with hormone receptor-positive early
breast cancer. The strength of this translational research
is its considerable sample size of 1967 patients, which
represents 74 % of women enrolled in TEXT. Further-
more, blood samples were collected specifically for this
research, i.e., to investigate treatment tolerability and
disease outcome. Women enrolled prior to the amend-
ment were asked to re-consent, but 693 TEXT partici-
pants were not assessed due to the retrospective nature
of blood collection. As a result, we may have missed
some patients who discontinued treatment early, pos-
sibly due to treatment-related side effects.
The combined analysis of TEXT and SOFT [4] showed
that adjuvant treatment with exemestane + OFS as com-
pared with tamoxifen + OFS, significantly reduces the
risk of recurrence. Although the overall incidence of ad-
verse events and the quality of life were similar in the
two treatment groups, between-group differences were
observed with respect to specific symptoms. While vaso-
motor AEs (hot flashes and sweating) were quite fre-
quent and evenly distributed amongst treatment groups,
Table 5 Associations of endpoints with SNP CYP19A1 rs10046 variants, overall and according to treatment assignments
CYP19A1: rs10046
Endpoint Cohort T/T vs T/C, C/C patients
(events)
Univariate model OR
(95 % CI)a
Univariate model Interaction
P valueb
Multivariable model
OR (95 % CI)c
Hot flashes/sweating All patients 446 (172) vs 1519 (676) 0.78 (0.63, 0.97) 0.03 0.83 (0.66, 1.03)
Exemestane + OFS 227 (77) vs 759 (334) 0.65 (0.48, 0.89) 0.67 (0.49, 0.93)
Tamoxifen + OFS 219 (95) vs 760 (342) 0.94 (0.69, 1.27) 1.04 (0.75, 1.43)
Musculoskeletal
events
All patients 446 (110) vs 1520 (406) 0.90 (0.70, 1.15) 0.39 0.85 (0.66, 1.1)
Exemestane + OFS 227 (75) vs 759 (256) 0.97 (0.71, 1.33) 0.96 (0.69, 1.32)
Tamoxifen + OFS 219 (35) vs 761 (150) 0.77 (0.52, 1.16) 0.77 (0.51, 1.17)
aEstimates from univariate logistic regression model. bP value from test of rs10046 variants ((T/T) vs. T/C, C/C) by treatment interaction in logistic regression model
(univariable) assessing association between the SNP variants and early-onset adverse events in the overall cohort. cAdjusted for baseline characteristics: age,
menstrual status, body mass index, adjuvant chemotherapy use, treatment assignment (for “all patients” cohort), baseline hot flashes/sweating or baseline
musculoskeletal symptoms (according to endpoint) and prior to or baseline concomitant medications use and use during relevant time period for the endpoint
(yes or no). SNP single nucleotide polymorphism, OFS ovarian function suppression, OR odds ratio, CI confidence interval
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musculoskeletal AEs were more frequently reported in
patients assigned to exemestane + OFS.
We did not observe any direct association between the
CYP19A1 SNPs and musculoskeletal symptoms, nor any
interaction by endocrine treatment. This is in contrast
with findings from the TEAM trial [30], but as mentioned
they studied a very small proportion of patients. Further-
more, genotyping in that study was performed on DNA
extracted from tumor samples. A cross-sectional study of
patients receiving AIs [34] found that women carrying at
least one 8-repeat allele of the tetranucleotide repeat poly-
morphism of CYP19A1, associated with higher estrogen
concentrations, had lower odds of AI-associated arthral-
gia. Conversely, they also did not find any association
between the rs10046 SNP and arthralgia.
Contrary to findings from case–control studies con-
ducted in different treatment settings, i.e., postmenopausal
or premenopausal women with breast cancer treated with
tamoxifen alone, we found no association between the
three ESR1 polymorphisms and endocrine-mediated side
effects (hot flashes/sweating and musculoskeletal symp-
toms). Postmenopausal Chinese patients with breast
cancer carrying an ESR1 rs2234693 CC genotype or
rs9340799 AA genotype had an increased risk of AI-
related musculoskeletal AEs [35]. In fact, several studies
suggest that the effect of the ESR1 polymorphisms on
breast cancer risk is hormone-related and dependent on
the woman’s hormonal context, showing statistically
significant associations mainly in premenopausal women
[23]. Likewise, an association with increased mammo-
graphic density [36] was shown only in women taking
hormone replacement therapy. Possibly, the concurrent
OFS by the GnRH analogue triptorelin masked the effect
of these polymorphisms due to its complete estrogen
deprivation effect. Thus, in the context of adjuvant com-
bined endocrine treatment, these ESR1 polymorphisms
may be unlikely to exert their effect.
Musculoskeletal events are a common toxicity, leading
to premature discontinuation of AI therapy [37]. In the
TEXT-SOFT combined analysis, early cessation of proto-
col treatment was more frequent among patients receiving
exemestane +OFS than among those receiving tamoxifen
+OFS. Several studies have investigated the relationship
between endocrine treatment efficacy and associated side
effects in different settings. Recent findings support an in-
verse association between the reporting of early side ef-
fects under adjuvant endocrine treatment and breast
cancer recurrence [38–40]. Vasomotor symptoms were as-
sociated with improved disease-free and overall survival in
the TEAM trial [38] and reduced breast cancer recurrence
in the ATAC trial [40], but not in the BIG 1–98 [41] and
MA.27 trials [42]. Thus, we cannot exclude that the
CYP19A1 rs10046 (T/T) genotype might be associated
with reduced exemestane +OFS efficacy: women with this
polymorphism possibly lack complete estrogen suppres-
sion, despite receiving concomitant OFS. On the other
hand, because the rs10046 polymorphism is located in a 3’
untranslated region, upstream of the coding sequence, it
may interfere with aromatase transcription in a tissue-
specific manner, depending on the transcriptional modula-
tors present, thus influencing the degradation rate of the
aromatase differently according to tissue and independ-
ently from circulating estrogen [9].
Conclusions
This translational study within the TEXT trial for premen-
opausal patients with hormone-receptor-positive early
breast cancer provides evidence that the CYP19A1
rs10046 polymorphism may influence endocrine treat-
ment side effects under combined endocrine therapy. The
CYP19A1 rs10046 variant favors lower incidence of hot
flashes/sweating under exemestane plus ovarian function
suppression treatment, suggesting endocrine-mediated ef-
fects that might enhance treatment adherence and poten-
tially impact long-term treatment efficacy. No effect of
any other tested SNPs was evident on hot flashes/sweating
and no interaction on musculoskeletal symptoms emerged
overall. Monitoring of musculoskeletal and bone events,
known to occur later during treatment are warranted.
Although our results must be considered hypothesis-
generating, longer follow up will allow us to assess the
clinical relevance of this finding, in particular its potential
impact on disease outcome, and will be the subject of a
future report after the TEXT results are further updated.
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